Skip To Main Content
Tlalit Barhod on Muck Rack

Tlalit Barhod

As seen in: Wiley Online Library
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Tlalit

Contact Tlalit, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Emicizumab in Previously Untreated Patients and Minimally Treated Patients With Hemophilia A: A Comparative Study Between Two International Cohorts

|
By Sarina Levy-Mendelovich, Tlalit Barhod, Ivan Budnik, Jonathan Lancashire
| Wiley Online Library Verified
1 Introduction Hemophilia A (HA) is a rare, X-linked bleeding disorder caused by a deficiency of coagulation factor VIII (FVIII) [1]. Standard treatment for severe HA has traditionally involved prophylactic FVIII intravenous replacement therapy [2].
Open in Who Shared Issue with article?

The Impact of Emicizumab Prophylaxis on Hospitalizations and Emergency Department Visits Among Hemophilia A Patients Is Age Related

|
By dan geller, Ivan Budnik, Omri Cohen, Tlalit Barhod
| Wiley Online Library Verified
1 Introduction Hemophilia A (HA) is a genetic disorder with an X-linked inheritance pattern, resulting from a mutation in the gene encoding coagulation factor VIII. This leads to recurrent bleeding events, primarily affecting joints and muscles [1]. Until recently, the conventional therapeutic strategy involved prophylactic intravenous infusions of factor VIII. Approximately 30% of patients develop inhibitory antibodies directed against the factor.
Open in Who Shared Issue with article?
See all 2 articles